-
National Health Commission: 3,070 critically ill newborn care centers have been established nationwide
Time of Update: 2021-06-17
Medical Network News, June 9th, 8th, the State Information Office held a press conference. Song Li, spokesperson for the National Health Commission, said that the health of minors is an important fo
-
National Medical Insurance Administration: DRG and DIP payment pilot cities will actually pay in 2021
Time of Update: 2021-06-17
Disease disease disease "Deepening the reform of the medical insurance payment method is an important measure for the development and improvement of the medical insurance system itself and the continuous improvement of the efficiency of the use of medical insurance funds.
-
Centralized procurement "big killer": the Guangxi version of the medical insurance balance retention policy is here!
Time of Update: 2021-06-17
On January 15 this year, according to the "Chongqing Daily" report, a total of 157 medical institutions in Chongqing participated in the first batch of national centralized procurement of 25 selected drugs and medical insurance fund balance retention assessment, of which 102 medical institutions passed the assessment and the balance medical insurance fund was 61,974,400 Yuan .
-
The fifth batch of supplementary documents issued by Guocai Shanghai!
Time of Update: 2021-06-17
The unselected highest-priced drugs of the same species that meet the requirements of this centralized procurement declaration can continue to be purchased and used after a gradual price reduction (based on the selected price) according to the price difference.
-
New indications for AstraZeneca olaparib tablets are about to be approved
Time of Update: 2021-06-17
On June 7, the official website of the State Food and Drug Administration showed that the application for the new indication for AstraZeneca olaparib (acceptance number: JXHS2100001) was in the "under
-
Nearly 20 original research drugs have encountered patent challenges!
Time of Update: 2021-06-17
Chongqing Yaoyou Pharmaceutical challenged the patent of this pharmaceutical preparation, and the State Intellectual Property Office made a complete invalidation decision on ZL200680007187.
Chongqing Yaoyou Pharmaceutical challenged the patent of this pharmaceutical preparation, and the State Intellectual Property Office made a complete invalidation decision on ZL200680007187.
-
Harbin Pharmaceutical Group: Simvastatin tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-06-17
② for pure hypercholesterolemia patients with homozygous familial, when diet and non-diet is not ideal, simvastatin can be used to reduce elevated total cholesterol, LDL cholesterol and apolipoprotein B .
② Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction .
-
Fierce competition among leading companies in the diabetes drug market for new drug development
Time of Update: 2021-06-17
The expansion of indications has become a market growth point In December 2019, Sanofi announced that it would stop research on new drugs for the treatment of diabetes and cardiovascular diseases, and shift to the field of autoimmunity and tumor treatment .
-
Pfizer and others go forward and continue AD research and development stagnant, can Bojian Aducanumab stand out?
Time of Update: 2021-06-17
Similarly, in the face of such urgent patient demand and market vacancies, in addition to the approval of the ninth phase one developed by Green Valley Pharmaceuticals, currently domestic companies including Hengrui, Dongyang Sunshine, Hisun and other companies have joined the track.
-
National Development and Reform Commission: Regional medical center construction will cover all provinces by the end of next year
Time of Update: 2021-06-17
On June 8th, regarding the construction of regional medical centers, Sun Zhicheng, head of the Department of Social Development of the National Development and Reform Commission, stated in Beijing on the 7th that 12 more provinces in the central and western regions with relatively short supply of high-quality medical resources will be included in the pilot program this year; By the end of next year, the construction of regional medical centers shall be covered in all provinces .
-
Blowouts in batches, stratification and classification have appeared, and the collection rules for high-value medical consumables continue to iterate
Time of Update: 2021-06-17
Medical Network, June 8th, June 4th, the National Medical Insurance Administration, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry o
-
Samsung Pharmaceuticals and GemVax submit new drug Phase III trial results
Time of Update: 2021-06-17
In 16 hospitals in South Korea (including Severance Hospital), the RIAVAX Phase III clinical trial was conducted with gemcitabine/capecitabine to study the safety and efficacy in 148 patients with locally advanced and metastatic pancreatic cancer Sex .
-
Sales of 5 star drugs have soared!
Time of Update: 2021-06-17
Sales of proprietary Chinese medicines in physical pharmacies in cities in China (unit: 100 million yuan) Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern Among the 13 treatment categories of proprietary Chinese medicines, medicines for respiratory diseases ranked first with a market share of 26.
-
Multi-departmental support for favorable policies frequently raises concerns about children's medication problems
Time of Update: 2021-06-17
(Zhan Ni, Public Opinion Monitoring Center of China Health Media Group) Medical Network News, June 9th, for a long time, the supply of special medicines for children has not been able to meet the clinical needs.
-
Scientific classification to ensure safety and service innovation——Analysis of "Principles of Classification and Definition of Recombinant Collagen Medical Products"
Time of Update: 2021-06-17
Medical Network News on June 10 A few days ago, the State Food and Drug Administration issued the "Classification and Definition Principles for Recombinant Collagen Medical Products" (hereinafter referred to as the "Classification and Definition Principles") to further clarify the management attributes of recombinant collagen medical products and the basis for determining management categories.
-
National Medical Insurance Administration: "Zero Tolerance" for Medical Insurance Fraud
Time of Update: 2021-06-17
Medical Network, June 7th, a reporter learned from the China National Medical Insurance Administration on the 6th that the bureau will soon inform the National Medical Insurance System of Anhui Province’s investigation of fraudulent insurance cases in Taihe County, and require medical insurance departments at all levels to deal with medical insurance fraud fraud.
-
Zhengda Tianqing is showing off!
Time of Update: 2021-06-17
Figure 1: The status of new drugs and generic products declared by Nanjing Chia Tai Tianqing since 2021 Source: CDE official website In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria .
-
The 2020 national "medical insurance bill" is released!
Time of Update: 2021-06-17
4% of the year’s GDP; the total expenditure of the national basic medical insurance fund (including maternity insurance) was 21,032 billion yuan, a year-on-year increase of 1.
-
The largest GPO!
Time of Update: 2021-06-17
In terms of centralized procurement and bargaining methods, the "Document" stipulates that the first category of drugs: the selected varieties purchased by the state and this city in a large amount shall be implemented at the selected prices and related regulations .
-
The first in China! Lepu Biologics TF ADC submits a clinical application for new drugs in China
Time of Update: 2021-06-17
On June 7, the new drug clinical trial application (IND) of the antibody-conjugated drug MRG004A that targets tissue factor (TF) submitted by Shanghai Miac, a wholly-owned subsidiary of Lepu Bio, was accepted by CDE .
